上天天基金APP搜索777注册即可领500元券包，优选基金10元起投！限量发放！先到先得！ 这位富豪下场了，华纳兄弟探索公司千亿美元收购案最新消息！ 贵金属大爆发！黄金、白银齐齐创历史新高！铂金也逼近历史高点。 美股三大指数集体收涨 美东时间12月22日，临近假日，美股交投清淡，主要指数集体上涨。美股三大指数已连涨三 日。 美东时间12月22日，美股三大指数集体收涨，开启了"圣诞老人行情"。 | 特斯拉(TESLA) | 488.730 | 1.56% | | --- | --- | --- | | TSLA.O | | | | 英伟达(NVIDIA) | 183.690 | 1.49% | | NVDA.O | | | | 谷歌(ALPHABET) | 309.780 | 0.85% | | GOOGL.O | | | | 亚马逊(AMAZON) AMZN.O | 228.430 | 0.48% | | 脸书(META PLATF | 661.500 | 0.41% | | META.O | | | | 微软(MICROSOFT | 484.715 | -0.25% | | MSFT.O | | | | 苹 ...

【导读】美股三大指数集体收涨 贵金属大爆发！黄金、白银齐齐创历史新高！铂金也逼近历史高点。 美股三大指数集体收涨 美东时间12月22日，临近假日，美股交投清淡，主要指数集体上涨。美股三大指数已连涨三日。 截至收盘，道指涨0.47%，报48362.68点；标普500指数涨0.64%，报6878.49点；纳指涨0.52%，报23428.83点。 默克涨超3%，摩根大通涨近2%，领涨道指。 消息面上，美国总统特朗普将在明年1月第一周指定美联储新主席人选。鲍威尔的四年主席任期将于明年5月届满，特朗普此前表示，他希望选择一位支持 增长友好型货币政策的继任者。 美联储理事米兰表示，如果美联储明年不继续降息，可能面临引发经济衰退的风险。他还表示，预计短期内不会出现经济下行，但失业率上升应促使美联 储官员继续降息。2026年票委、克利夫兰联储主席哈马克表示，在美联储最近连续三次会议降息之后，她认为未来几个月没有必要调整利率。她此前曾反 对近期的降息决定，更担心通胀居高不下而非劳动力市场疲软。 美财长贝森特表示，通胀正在向美联储2%的目标迈进，2026年将成为经济增长与通胀走势向好的一年，随着政府职位减少，经济状况会变得更好。 ...

【导读】美股三大指数集体收涨 中国基金报记者 伊万 美东时间12月22日，美股三大指数集体收涨，开启了"圣诞老人行情"。 这位富豪下场了，华纳兄弟探索公司千亿美元收购案最新消息！ 贵金属大爆发！黄金、白银齐齐创历史新高！铂金也逼近历史高点。 美股三大指数集体收涨 美东时间12月22日，临近假日，美股交投清淡，主要指数集体上涨。美股三大指数已连涨三日。 截至收盘，道指涨0.47%，报48362.68点；标普500指数涨0.64%，报6878.49点；纳指涨0.52%，报23428.83点。 默克涨超3%，摩根大通涨近2%，领涨道指。 贵金属近日表现火热，现货黄金和现货白银双双创历史新高。 12月22日美股盘中，现货黄金涨2.48%至4449.18美元/盎司，创历史新高，全天持续走高。现货白银涨2.79%，报69.0304美元/盎司， 之后持续上涨，触及69.4549美元的历史新高。 截至发稿，现货黄金和现货白银仍在上涨。 消息面上，美国总统特朗普将在明年1月第一周指定美联储新主席人选。鲍威尔的四年主席任期将于明年5月届满，特朗普此前表示，他希 望选择一位支持增长友好型货币政策的继任者。 美联储理事米兰表示，如果 ...

Core Viewpoint - The National Medical Products Administration (NMPA) has approved Pimicotinib capsules for the treatment of symptomatic tenosynovial giant cell tumors (TGCT) in adult patients, which may lead to functional limitations or serious complications [1] Group 1: Product Approval - Pimicotinib (development code: ABSK021) is a novel, oral, highly selective, and effective small molecule CSF-1R inhibitor developed independently by He Yu Pharmaceutical [1] - The approval was granted through the CDE priority review process [1] Group 2: Licensing Agreement - In December 2023, He Yu Pharmaceutical entered into an exclusive licensing agreement with Merck for Pimicotinib [1] - Under the agreement, Merck obtained exclusive rights for the commercialization of Pimicotinib for all indications in mainland China, Hong Kong, Macau, and Taiwan, along with exclusive options for global commercialization rights [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Abbisko Cayman Limited 和譽開曼有限責任公司 （於開曼群島註冊成立的有限公司） （股份代號：2256） 內幕消息 和譽醫藥CSF-1R抑制劑貝捷邁®獲中國NMPA批准 本公告由和譽開曼有限責任公司（「本公司」，連同其附屬公司統稱「本集團」）根據 《香港聯合交易所有限公司證券上市規則》（「上市規則」）第13.09(2)(a)條和香港法 例第571章《證券及期貨條例》第XIVA部項下的內幕消息條文（定義見上市規則） 作出。 本公司謹此告知本公司股東及潛在投資者，如隨附之新聞稿所述，2025年12月22 日，本公司之附屬公司上海和譽生物醫藥科技有限公司（「和譽醫藥」）宣佈，中國 國家藥品監督管理局（「NMPA」）批准貝捷邁® （鹽酸匹米替尼膠囊），適用於手術 切除可能會導致功能受限或出現較嚴重併發症的症狀性腱鞘巨細胞瘤（「TGCT」） 成年患者。獲批後，默克將盡快推動該產品惠及中國TGC ...

Core Viewpoint - Merck has recently made significant announcements, including the appointment of a new CEO and the acquisition of JSR Life Sciences' chromatography business, aimed at enhancing its biopharmaceutical production capabilities [4]. Group 1: Leadership Changes - Merck officially announced the appointment of Kai Beckmann as the new CEO, effective May 1, 2026 [4]. - Rogier Janssens will take over as the President of Merck China starting February 1, 2026, and will also lead Merck Life Science in China from January 1, 2026, to improve market responsiveness [5][10]. - Current President of Merck China, Marc Horn, will return to Germany for family reasons after contributing significantly to the company's operations and reputation in China over the past two years [6][13]. Group 2: Strategic Acquisitions - Merck announced the acquisition of JSR Life Sciences' chromatography business on October 15, 2023, which is expected to enhance its downstream product offerings and support more efficient biopharmaceutical production [4]. Group 3: Commitment to China - Merck has invested nearly 7 billion RMB in China over the past decade, establishing a strong local presence with approximately 4,500 employees and 21 legal entities [13]. - The company aims to continue deepening its engagement in China, aligning its three main business areas—Life Science, Healthcare, and Electronics—with national strategies to drive sustainable growth and innovation [8][13].

Domestic Market Overview - The A-share market opened positively in December, with the Shanghai Composite Index closing at 3914.01 points, up 0.65%, and the Shenzhen Component Index closing at 13146.72 points, up 1.25% [1][4] - A total of 27 out of 30 CITIC first-level industries saw an increase, with consumer services, non-ferrous metals, and telecommunications leading the gains, while only comprehensive finance, agriculture, forestry, animal husbandry, and real estate experienced slight declines [1][4] - The total trading volume of the entire A-share market reached 18894 billion, showing an increase compared to the previous day [1][4] Overseas Market Overview - The three major U.S. stock indices all closed lower, with the Dow Jones falling by 0.9%, the S&P 500 down by 0.53%, and the Nasdaq decreasing by 0.38% [2][4] - Merck's stock dropped nearly 3%, and Amgen fell over 2%, leading the decline in the Dow [2][4] - Chinese concept stocks mostly rose, with NetEase increasing by approximately 5% and Alibaba rising over 4% [2][4] News Highlights - The Ministry of Public Security and ten other departments jointly issued opinions on strengthening the ecological police mechanism [3][11] - The Ministry of Industry and Information Technology held a symposium for the manufacturing enterprises in the power and energy storage battery industry [3][12] - The China Securities Regulatory Commission is soliciting public opinions on the pilot announcement for commercial real estate investment trust funds [3][13][15] - The Chinese Center for Disease Control and Prevention reported that national influenza activity has reached a moderate level, with some provinces at a high level [3][16] - Starting from now until September 14, 2026, Chinese citizens can travel to Russia without a visa [3][17] - Important global economic data has been released [3][18]

Core Viewpoint - Merck's new semiconductor materials plant in southern Taiwan, with an investment of €500 million ($579 million), has begun the qualification process before mass production of materials for AI chip manufacturing, expected to start in 2026 [1][2]. Group 1: Plant Details and Production Capacity - The new facility, located in Kaohsiung, Taiwan, spans approximately 150,000 square meters and will produce thin films, formulation materials, and specialty gases essential for advanced chip manufacturing [1]. - Once operational, the plant is projected to meet about 80% of the local demand for thin film materials and over 50% of the overall material needs [1]. - The production of advanced chips, such as 3nm and beyond, involves over 1,000 processing steps, increasing the demand for materials [2]. Group 2: Strategic Importance and Local Impact - Merck has adopted a localization strategy over the past six to seven years to better serve customers and enhance supply chain resilience [1]. - The new plant is expected to improve local self-sufficiency from over 50% and play a significant role in meeting demand in the Asia-Pacific region [2]. - The facility will create approximately 400 jobs as it scales up production [3]. Group 3: Collaboration and Quality Assurance - Collaboration with customers in their factories is crucial for chip material manufacturers due to the importance of material integration and customization in chip production [2]. - Strict validation processes are required before the chemicals and materials produced can be widely used in advanced semiconductor production lines [2].

Investment Rating - The report assigns a "Buy" rating for the company, marking it as a first-time recommendation [11]. Core Insights - The pearl materials industry is experiencing steady growth, driven by increasing demand in high-end sectors such as automotive and cosmetics. The industry is undergoing a transformation, with domestic companies accelerating their entry into high-end markets through mergers and acquisitions and technological advancements. As a global leader, the company leverages its integrated advantages in synthetic mica, core technology research and development, and capacity expansion to ensure rapid internal growth. The acquisition of Korean CQV and Merck's surface solutions business fills gaps in high-end products and channels, achieving diversified synergy. With deepening integration and capacity release, the company is expected to solidify its global leadership position and fully benefit from the industry's high-endization [3][6][8]. Summary by Sections Pearl Materials: Demand Growth and Structural Upgrade - Pearl materials are special optical effect materials that display a pearl-like luster, produced by coating substrates with one or more layers of metal oxides. They are used in high-color-requirement fields such as automotive, cosmetics, and coatings. Compared to other pigments, pearl materials are safe, non-toxic, vibrant in color, and have strong weather resistance. The global pearl materials market is rapidly growing, with a compound annual growth rate (CAGR) of 14.0% from 2016 to 2023, reaching sales of 23.5 billion in 2023. Emerging substrate pearl materials, such as synthetic mica, silica, and alumina, have significantly outpaced overall growth, with CAGRs of 45.7%, 33.1%, and 25.0% respectively from 2016 to 2020 [6][7][28]. Application Scenarios and High-End Demand - Pearl materials have broad downstream applications categorized into industrial-grade, cosmetic-grade, and automotive-grade. The automotive and cosmetic sectors primarily focus on mid-to-high-end products. In 2023, the market shares for cosmetic and automotive pearl materials were approximately 6.8% and 16.2%, with CAGRs of 33.9% and 15.6% from 2016 to 2023, respectively. The high-end demand is expected to maintain around 15% growth, driven by stable industry demand and increased penetration from product upgrades [7][28][32]. Industry Landscape Transformation - The industry is witnessing a shift towards high-end markets, with domestic brands making significant strides. The market concentration of the top five companies (CR5) is projected to be around 19% in 2024, with the company achieving a market share close to 12% after acquiring Merck's pearl business and CQV, making it the global leader. Historically, the high-end market has been dominated by overseas brands, with a CR5 concentration of 52% [7][8][28]. Company Overview - The company, established in 2011, focuses on the production and sale of pearl materials and synthetic mica. It went public in Hong Kong in 2021. The second phase of its pearl materials project, with an annual capacity of 30,000 tons, is set to commence in 2024, making it the largest pearl materials factory in China. The company is also concentrating on synthetic mica, with a 100,000-ton project in Tonglu starting in 2025. The acquisitions of CQV and Merck's surface solutions business in 2023 and 2025, respectively, are expected to facilitate rapid global expansion and growth [8][9][28]. Capacity Expansion and Growth Acceleration - The company currently has a total capacity of 48,000 tons for pearl pigments across its two factories in Guangxi. The ongoing construction of a 100,000-ton synthetic mica facility in Hangzhou will further support revenue growth. The company aims to enhance its market share through capacity expansion and leverage the advantages of its acquisitions to penetrate high-end markets [9][28]. Strategic Synergy and Future Outlook - The company anticipates achieving a synergistic effect from its acquisitions, optimizing costs and enhancing product integration. The expected net profits for 2026 and 2027 are projected to be approximately 490 million and 720 million, respectively, corresponding to price-earnings ratios of 17.73 and 11.99 [9][28].

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. is focused on innovative drug development and aims to enhance its capabilities through an IPO on the Sci-Tech Innovation Board, raising approximately 1.185 billion RMB for various projects [9][10][35]. Company Overview - Baiaosaitu is an innovative preclinical CRO and biotechnology company established in 2009, specializing in gene editing technology and providing various preclinical drug development services [12]. - The company has developed four major technology platforms: gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [7][12]. Business Model and Services - The company addresses two core challenges in antibody drug development: obtaining high-quality antibody molecules and the lack of precise evaluation models [8]. - Baiaosaitu has created a comprehensive human antibody library and a humanized mouse library, enabling the discovery of antibody candidates against over 1,000 potential drug targets [8][16]. - The company has established partnerships with top global pharmaceutical companies, enhancing its credibility and accelerating its international business expansion [8][14]. Financial Overview - The company expects to raise 1.185 billion RMB through its IPO, which will be used for upgrading early drug development service platforms, antibody drug research, and enhancing preclinical research projects [9][35]. - The company's main business revenue has shown a compound annual growth rate of 35.56% over the past three years, with revenues of approximately 533.36 million RMB, 716.40 million RMB, and 980.07 million RMB in recent years [22]. Future Development Plans - The company plans to continue promoting its "Thousand Mice and Ten Thousand Antibodies" initiative, aiming to discover novel antibody candidates for external collaboration or internal development [24]. - Baiaosaitu intends to expand its preclinical product and service offerings, particularly in oncology, autoimmune diseases, cardiovascular, metabolic, and neurological disorders [24][25]. - The company aims to establish extensive partnerships with leading pharmaceutical and biotechnology companies both domestically and internationally [25]. Competitive Advantages - The company possesses leading gene editing technology, a comprehensive range of model animals, and a significant first-mover advantage in antibody development [27]. - The unique "Thousand Mice and Ten Thousand Antibodies" plan provides flexibility in research, collaboration, and business models, enhancing its competitive edge [27]. Regulatory and Market Position - Baiaosaitu has received AAALAC certification, ensuring compliance with international standards for laboratory animal care [20]. - The company meets the listing standards for the Sci-Tech Innovation Board, with an expected market value of no less than 3 billion RMB and recent annual revenue exceeding 300 million RMB [32].